Economic and Societal Challenges
Major Advances in the Treatment of Lymphomas, but still Unmet Medical Needs
Despite an important improvement in patient survival thanks to immunotherapy since 1997, the demands in R&D are ample in order to achieve solid personalized medicine for lymphoma:
- More targeted, better tolerated and more effective drugs
- Improved therapeutic combinations
- Biological and imaging markers to refine diagnosis and prognosis and to select the population for targeted therapy
- Accelerated transfer researchfrom bench to bedside
- Faster clinical studies, especially in the early phases
- Decreased rate of attritionin clinical research
Lymphoma Drug Market: Attractive and Dynamic
The value of the global NHL treatment market is expected to reach $9.2 billion by 2020 from $5.6 billion in 2013 at a Compound Annual Growth Rate (CAGR) of 7.4% (source: GBI Research).
The HL market will increase approximately four-fold between 2016 and 2024, reaching $1.4 billion by 2024 at a CAGR of 16% (source : GlobalData).
In 2015 (source Thomson Reuters Cortellis):
- 153 drugs in development for NHL, of which 77 in late phase development
- 14 drugs in development for HL, 5 in late phase development
In vitro diagnostics
The European market reached 10.5 billion euros in 2015 (source : European Diagnostic Manufacturers Association), with a growing weight of biomarkers and personalized medicine. The global IVD market is estimated to grow at an annual rate of 5.2% through 2023, in terms of revenue, and is expected to reach $76 billion by 2023 (source : BIS Research).
With the growing role of computed tomography and positron emission tomography for the diagnosis and monitoring of patients, the imaging market accounted for 23.5 billion dollars in revenue in 2015.The projections of 33.5 billion in 2021, with a growth of 6% per year (source : Zion Market Research).